- Record: found
- Abstract: found
- Article: not found
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Leena Gandhi
1 ,
D Ross Camidge ,
Moacyr Ribeiro de Oliveira ,
Philip Bonomi ,
David Gandara ,
Divis Khaira ,
Christine L Hann ,
Evelyn M McKeegan ,
Elizabeth Litvinovich ,
Philip M Hemken ,
Caroline Dive ,
Sari H Enschede ,
Cathy Nolan ,
Yi-Lin Chiu ,
Todd Busman ,
Hao Xiong ,
Andrew P Krivoshik ,
Rod Humerickhouse ,
Geoffrey I Shapiro ,
Charles M Rudin
Mar 01 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors.